Evotec SE (EVO) Other Non-Current Assets (2009 - 2026)
Evotec SE (EVO) reported Other Non-Current Assets of $489.37 for Q1 2026, down 84.24% on a YoY basis from $3105.2 in Q1 2025, and down 17.08% sequentially from $590.17 in Q4 2025.
Evotec SE (EVO) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Other Non-Current Assets data on file, last reported at $489.37 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 84.24% year-over-year to $489.37; the trailing twelve-month figure through Mar 2026 stood at $489.37 (down 84.24% YoY), and the FY2025 full-year result was $590.17, down 99.98% from the prior year.
- Other Non-Current Assets retreated to $489.37 in Q1 2026, from $590.17 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $3.9 million in Q4 2022 to a low of $489.37 in Q1 2026.
- A 5-year average of $706938.8 and a median of $2122.5 in 2025 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets jumped 488.42% in 2022 and slumped 99.98% in 2025, its largest moves.
- Tracing EVO's Other Non-Current Assets over 5 years: stood at $3.9 million in 2022, then sank by 76.68% to $900561.7 in 2023, then soared by 311.03% to $3.7 million in 2024, then tumbled by 99.98% to $590.17 in 2025, then decreased by 17.08% to $489.37 in 2026.
- Business Quant data shows EVO's Other Non-Current Assets at $489.37 in Q1 2026, $590.17 in Q4 2025, and $889.65 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 489.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 489.37 |
| Dec 31, 2025 | 590.17 |
| Sep 30, 2025 | 889.65 |
| Jun 30, 2025 | 1,139.88 |
| Mar 31, 2025 | 3,105.16 |
| Dec 31, 2024 | 3.70 Mn |
| Mar 31, 2024 | 924.49 |
| Dec 31, 2023 | 900,561.70 |
| Dec 31, 2022 | 3.86 Mn |
| Sep 30, 2022 | 5,891.35 |
| Jun 30, 2022 | 5,453.73 |
| Mar 31, 2022 | 969.70 |
| Dec 31, 2021 | 5.89 Mn |
| Sep 30, 2021 | 1,001.21 |
| Dec 31, 2020 | 26,230.38 |
| Sep 30, 2010 | 3,977.12 |
| Jun 30, 2010 | 3,937.97 |
| Mar 31, 2010 | 5.04 |
| Dec 31, 2009 | 5,415.18 |
| Jun 30, 2009 | 2.13 Mn |